NBIX

Neurocrine Biosciences Inc

$169.00

1.47 (0.86%) Today

0.47 (0.28%) After-hours

— up— down

Compare NBIX

Market Cap

$16.95B+34.1%

Revenue (TTM)

$3.02B+28.6%

Net Income (TTM)

$653.59M+120.3%

EPS (TTM)

6.50+120.3%

Shares Out

100.55M

P/E Ratio

25.57

Forward P/E

19.02

Open

$170.44

Previous Close

$170.00

Day Range

$168.24 – $171.50

52-Week Range

$122.14 – $171.50

Beta

0.39

Volume

1.02M

Avg Volume

1.16M

Analyst Rating

Buy

Exchange

NASDAQ NMS - GLOBAL MARKET

About NBIX

Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).